Interferon beta 1-b in combination with azathioprine for secondary progressive multiple sclerosis. preliminary safety and tolerability data from a 2-year double blind, randomized, multicentre, pilot study.
L. Manneschi, Luca Durelli(University of Turin), Elio Scarpini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Ilaria Pesci, Emilio Morelli, L. Motti(Santa Maria Nuova Hospital), M. R. Tola(Vita-Salute San Raffaele University), E. Montanari(University of Milan), D. Caputo, A. Ghezzi(Azienda Ospedaliera Sant’Antonio Abate di Gallarate)
Unknown
January 1, 2004
Cited by 0
Related Papers
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study
|The Lancet|2001|1.1k
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)
|The Lancet|2002|552
Evidence of early cortical atrophy in MS
|Neurology|2003|485
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study
|Multiple Sclerosis Journal|2015|298
Clinical characteristics, course and prognosis of relapsing Devic?s Neuromyelitis Optica
|Journal of Neurology|2004|268